EUVIMEDEUVIMED entdecken
Crossref

Unnatural Amino Acid Substitutions to Improve In Vivo GRPR-Targeting Capability of [68Ga]Ga-SP01011 for Cancer Imaging

Sheetal Pathania, Chao-Cheng Chen, Pauline Ng, Helen Merkens, Wing Sum Lau, Joseph Lau iD, François Bénard iD, Kuo-Shyan Lin iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.6c00854 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Sheetal Pathania und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, British ColumbiaV5Z 1L3, Canada. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Radiopharmaceuticals, Receptors, Bombesin, Amino Acid Substitution. Die Arbeit nennt 38 Literaturangaben. Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastrin-releasing peptide receptor (GRPR) shows elevated expression in several malignancies and represents an attractive target in cancer imaging and radioligand therapy. However, improving in vivo stability without compromising high tumor uptake and low pancreatic uptake remains a key challenge for the development of GRPR-targeted radiopharmaceuticals. In the present study, we investigated whether incorporating unnatural amino acid substitutions at potential cleavage sites of the previously reported GRPR-targeted agonist [68Ga]Ga-SP01011 (Ga-DOTA-Pip-d-Phe-Gln7-Trp8-Ala9-Val10-Gly11-His12-Leu13-Ac6c14-NH2; Ac6c: 1-amino-1-cyclohexanecarboxylic acid) could enhance in vivo stability without compromising tumor-targeting capability. SP01012, SP01013, and SP01019 incorporating NMe-His12, Ala(tBu)13 and Tle10/NMe-His12 substitutions, respectively, were synthesized by Fmoc solid-phase peptide synthesis and obtained in 22–60% yield. Their corresponding nonradioactive Ga complexes were obtained in 58–89% yield by reacting the DOTA-conjugated precursors with excess GaCl3 in acetate buffer, and the products were subsequently purified by HPLC. In vitro competition binding assays demonstrated that the Ki values of Ga-SP01012, Ga-SP01013 and Ga-SP01019 were 1.36 ± 0.12, 11.5 ± 0.89 and 2.29 ± 0.77 nM, respectively. All three ligands retained agonistic characteristics as confirmed by the calcium release assay. Their 68Ga-labeled analogs were obtained by reacting the precursors with [68Ga]GaCl3 in HEPES buffer with microwave heating (100 °C, 1 min). Following HPLC purification, 68Ga-labeled tracers were obtained in 33–47% decay-corrected radiochemical yield with radiochemical purities >95%. PET/CT imaging together with ex vivo biodistribution analyses conducted at 1 h postinjection in PC-3 tumor-bearing mice demonstrated clear tumor visualization and predominantly renal excretion for all three tracers. Among them, [68Ga]Ga-SP01012 containing the NMe-His12 substitution alone, had the most favorable profile, with the highest tumor uptake (15.8 ± 0.65% ID/g), low pancreas uptake (1.27 ± 0.32% ID/g), and improved in vivo plasma stability (78.1 ± 0.83% intact tracer at 15 min postinjection compared to 63.5 ± 6.24% for [68Ga]Ga-SP01011). In contrast, [68Ga]Ga-SP01019, containing both Tle10 and NMe-His12 substitutions, showed the highest plasma stability (88.3 ± 2.90% intact tracer at 15 min postinjection), but this was accompanied by lower tumor uptake (12.4 ± 1.54% ID/g) and markedly increased pancreas uptake (23.7 ± 3.47% ID/g). [68Ga]Ga-SP01013, containing the Ala(tBu)13 substitution, showed reduced GRPR binding affinity and lower tumor uptake (8.33 ± 1.41% ID/g). Our findings indicate that [68Ga]Ga-SP01012 is a potential PET tracer for visualizing GRPR-expressing tumors, and the NMe-His12 substitution is a favorable modification for the design of GRPR-targeted agonist-based radiopharmaceuticals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gallium RadioisotopesRadiopharmaceuticalsReceptors, BombesinAmino Acid SubstitutionNeoplasmsAnimalsMiceHumansTissue DistributionCell Line, TumorHeterocyclic Compounds, 1-RingPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

gallium-68gastrin-releasing peptide receptorin vivo stabilitypancreas uptakepositron emission tomography

Substanzen

Gallium RadioisotopesRadiopharmaceuticalsReceptors, BombesinGallium-68Heterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, British ColumbiaV5Z 1L3, Canada.
  • Department of Radiology, University of British Columbia, Vancouver, British ColumbiaV5Z 1M9, Canada.
  • Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, British ColumbiaV5Z 4E6, Canada.

ORCID-Profile: Joseph Lau, François Bénard, Kuo-Shyan Lin

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Pathania, S., Chen, C. C., Ng, P., Merkens, H., Lau, W. S., Lau, J., Bénard, F., & Lin, K. S. (2026). Unnatural Amino Acid Substitutions to Improve In Vivo GRPR-Targeting Capability of [68Ga]Ga-SP01011 for Cancer Imaging. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00854

Vancouver

Pathania S, Chen CC, Ng P, Merkens H, Lau WS, Lau J, et al. Unnatural Amino Acid Substitutions to Improve In Vivo GRPR-Targeting Capability of [68Ga]Ga-SP01011 for Cancer Imaging. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00854

BibTeX
@article{Pathania2026,
  author = {Pathania, Sheetal and Chen, Chao-Cheng and Ng, Pauline and Merkens, Helen and Lau, Wing Sum and Lau, Joseph and Bénard, François and Lin, Kuo-Shyan},
  title = {Unnatural Amino Acid Substitutions to Improve In Vivo GRPR-Targeting Capability of [68Ga]Ga-SP01011 for Cancer Imaging},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.6c00854}
}
Kostenlos starten →